Rune Labs and Aspen Neuroscience Collaborate on Parkinson’s Disease Study
Rune Labs, a leading precision neurology software and data platform company, has joined forces with Aspen Neuroscience Inc., a prominent autologous cell therapy biotechnology firm. The collaboration aims to leverage Rune Labs’ StriveStudy clinical development platform, enabling Aspen to gather real-time, longitudinal patient data remotely. The primary objective of this partnership is to utilize the […]
Aspen’s Breakthrough FDA-Cleared Parkinson’s Cell Therapy Unveiled
Aspen Neuroscience has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ANPD001, an autologous cell therapy designed to treat Parkinson’s Disease (PD) by replacing lost dopamine neurons. The clearance enables Aspen to initiate a first-in-patient Phase 1/2a clinical trial for individuals with moderate to severe […]
Stem Cells vs. Parkinson’s: The Battle of the Century
Welcome! We’re delighted to have you join us on this exploration into a topic that is at the forefront of medical research: the potential of stem cell treatments for Parkinson’s disease. You might be asking, “What exactly is Parkinson’s disease?” It’s a crucial question and one that we need to address before we delve deeper […]
Groundbreaking Trials Aim to Combat Parkinson’s with Patients’ Own Cells
San Diego-based startup Aspen Neuroscience plans to test the potential of lab-cultured brain cells, derived from a person’s own cells, to reverse Parkinson’s disease symptoms in human trials later this year. The company aims to determine if these injected cells can develop into dopamine-producing neurons, alleviating the disease’s debilitating symptoms. Animal tests have shown promise […]
Unlocking the Potential of Stem Cell Therapy in Treating Parkinson’s Disease
Stem cell therapy is an emerging and promising treatment method that has been linked to various diseases, such as Parkinson’s Disease. Stem cells are unique in their ability to develop into specialized cells, tissues, and organs, which allows them to replace cells that have been damaged or lost due to disease. In the context of […]
Exploring Stem Cell Therapy for Parkinson’s Disease
Parkinson’s disease is a progressive neurological disorder that affects millions of people around the world. While there currently is no cure, advances in stem cell research have offered new hope for those living with this chronic condition. In this blog post, we will delve into the potential benefits and risks associated with stem cell treatments […]
Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank
SAN DIEGO, Dec. 21, 2022 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), has signed a $40 million credit facility with Silicon Valley Bank (SVB). Deal terms were not disclosed. “We are pleased to work with Silicon Valley Bank. As a leader […]
Parkinson’s & Stem Cell Therapy Research
Stem cells are the body’s building blocks, capable of multiplying itself and creating other differentiated cells. Every day, scientists are learning more and more about their potential, and the use of these cells as an internal repair system. From laboratory test tubes to human trials, stem cells are giving new hope to a myriad of […]
NeuriTest™ Presented Publicly for the First Time at the International Society for Stem Cell Research Annual Meeting
SAN DIEGO, June 22, 2022 /PRNewswire/ — Aspen Neuroscience, Inc. Director of Bioinformatics, Roy Williams, Ph.D., presented NeuriTest™ for the first time publicly last week at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting in San Francisco, Calif. Dr. Williams’ podium presentation, “NeuriTest: A Bioinformatics-based Tool for Quality Control of iPSC-derived Dopamine Neuron Precursors […]
Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies
NEW YORK, June 9, 2022 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced data demonstrating a statistically significant (p<0.01) 19% downregulation of mRNA and a ~40% reduction of alpha synuclein (α-synuclein) in an in vitro study […]